IRF4/DUSP22 Test: Booking, Price, and Results
About IRF4/DUSP22 Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | DUSP22/IRF4 FISH, 6p25.3 Rearrangement FISH, IRF4 Break-Apart FISH, DUSP22-IRF4 Gene Rearrangement Test |
| Sample Type | Formalin-fixed paraffin-embedded (FFPE) tumour tissue block |
| Fasting Required | No |
| Report Time | 8 Days |
| Recommended For | Patients with suspected anaplastic large cell lymphoma or large B-cell lymphoma; adults and children requiring lymphoma subtyping |
| Price | Starting at ₹8,400 |
What Is an IRF4/DUSP22 Test?
The IRF4/DUSP22 test is a specialised genetic test that detects rearrangements in two genes, IRF4 (interferon regulatory factor 4) and DUSP22 (dual specificity phosphatase 22), located on chromosome 6p25.3. It is performed using a laboratory technique called FISH (fluorescence in situ hybridisation), which uses fluorescent probes to identify chromosomal changes in tumour cells. Doctors order this test to help classify certain types of lymphoma and assess a patient's prognosis. The test is also known as the DUSP22/IRF4 FISH test or the 6p25.3 Rearrangement FISH test.
What Does an IRF4/DUSP22 Test Measure?
The IRF4/DUSP22 test procedure analyses tumour tissue at a chromosomal level using a dual-colour break-apart probe. Here is what the test examines:
| Component | What It Detects |
|---|---|
| 6p25.3 Rearrangement Status | Whether a translocation (chromosomal rearrangement) has occurred at the IRF4/DUSP22 gene locus |
| Signal Pattern | Whether fluorescent probe signals remain joined (normal) or separate ("break apart"), indicating a rearrangement in the tumour cells |
The test does not distinguish between an IRF4 rearrangement and a DUSP22 rearrangement specifically; it reports whether a rearrangement at the 6p25.3 locus is present or absent.
Why Is an IRF4/DUSP22 Test Done?
Doctors request the IRF4/DUSP22 test when a biopsy suggests a specific type of lymphoma that requires genetic confirmation for accurate classification. The test results guide diagnosis and help oncologists assess expected outcomes.
Common Symptoms That May Require This Test
The following symptoms may prompt a doctor to investigate for lymphoma, which could lead to an IRF4/DUSP22 test being ordered:
- Painless swelling of the lymph nodes (in the neck, armpit, or groin)
- Unexplained weight loss
- Persistent fever without a clear cause
- Drenching night sweats
- Persistent tiredness or fatigue
- Skin rash or unexplained itching
- Loss of appetite
Conditions This Test Can Help Detect
This test supports the diagnosis of several haematological conditions. These include:
- ALK-negative anaplastic large cell lymphoma (ALCL), where a DUSP22/IRF4 rearrangement is associated with a more favourable outcome
- Large B-cell lymphoma with IRF4 rearrangement, a distinct subtype of non-Hodgkin lymphoma seen more commonly in children and young adults
- Cutaneous T-cell lymphoma (a type of lymphoma affecting the skin) linked to rearrangements at the 6p25.3 locus
- Certain other B-cell lymphomas, myeloma, and chronic B-cell lymphoid leukaemia where 6p25.3 rearrangements have been described
How to Prepare and What to Expect
The IRF4/DUSP22 test is performed on tumour tissue, not a blood sample. Preparation primarily involves ensuring that the correct tissue sample is available and properly processed before submission to the laboratory.
Do You Need to Fast?
No fasting is required for this test. Since the sample is tumour tissue collected via biopsy rather than a blood draw, dietary restrictions do not apply.
Practical Tips Before Your Test
Before submitting the sample, keep the following points in mind:
- Ensure a tumour biopsy (such as a lymph node or skin biopsy) has already been performed by your clinician
- The tissue must be fixed in 10% neutral buffered formalin and embedded in paraffin (FFPE format)
- Bring a detailed clinical history including your symptoms, previous test results, and relevant medical records, as this is required for the test
- Provide any available histopathology reports to the laboratory along with the tissue block
- Transport the FFPE tissue block at ambient temperature (18 to 28 degrees Celsius) and protect it from excessive heat
- Inform your doctor about all current medications and any prior treatments received
Step-by-Step Procedure
The IRF4/DUSP22 test procedure involves the following steps:
- A clinician performs a tumour biopsy (for example, from a lymph node or skin lesion), and the tissue is processed into an FFPE block at a pathology facility.
- Thin sections of the tissue are cut from the block, deparaffinised, and treated to allow fluorescent probes to reach the target DNA within the tumour cells.
- Fluorescent-labelled break-apart probes targeting the IRF4/DUSP22 region at chromosome 6p25.3 are applied to the tissue sections and left to hybridise overnight.
- The slides are washed and stained with a blue fluorescent dye (DAPI) that highlights the cell nuclei, making them easier to visualise.
- A specialist examines the slides under a fluorescence microscope, counting signal patterns in tumour cell nuclei to determine whether a rearrangement is present.
- Results are compiled by the laboratory and reported to the referring doctor, typically within 8 days.
Factors That Can Affect Accuracy
Several factors may influence the reliability of this test:
- Poor fixation or preservation of the tumour tissue
- Insufficient tumour cell content in the submitted sample
- Tissue section thickness outside the recommended range (4 to 6 microns)
- Exposure of the sample to excessive heat during transport
- Technical proficiency in FISH analysis and signal interpretation
Understanding Your IRF4/DUSP22 Test Results
Results of the IRF4/DUSP22 FISH test must always be reviewed by a haematopathologist or oncologist alongside clinical findings, histopathology, and immunohistochemistry reports. The table below outlines how results are generally interpreted.
| Result | Interpretation |
|---|---|
| Negative (No rearrangement) | The IRF4/DUSP22 gene locus is intact; no chromosomal translocation detected. Does not exclude lymphoma. |
| Positive (Rearrangement detected) | Supports a diagnosis of ALK-negative ALCL with DUSP22/IRF4 rearrangement, large B-cell lymphoma with IRF4 rearrangement, or certain other lymphoma subtypes, depending on clinical context. |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
A positive DUSP22/IRF4 rearrangement in ALK-negative ALCL has been associated with better outcomes in some studies, including high rates of complete remission after initial treatment. However, more recent research shows that outcomes can vary, and results must be discussed with your oncologist in full context.
How to Maintain Healthy Levels
This test is used specifically for lymphoma diagnosis and does not have direct lifestyle implications. The following general steps are relevant after receiving results:
- Attend all scheduled follow-up appointments with your haemato-oncologist
- Report any new or worsening symptoms, such as swollen lymph nodes, unexplained fever, or significant weight loss, to your doctor promptly
- Maintain open communication with your medical team regarding treatment progress and any side effects
Lupin Diagnostics IRF4/DUSP22 Test Price
The IRF4/DUSP22 test cost at Lupin Diagnostics starts at ₹8,400. This test requires a visit to a Lupin Diagnostics centre; home collection is not available, as the sample is an FFPE tissue block obtained from a biopsy procedure performed in a clinical setting.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 8400 |
| CHENNAI | 8400 |
| HYDERABAD | 8400 |
| KOLKATA | 8400 |
| NAVI MUMBAI | 8400 |
| PUNE | 8400 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book the IRF4/DUSP22 test online:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample submission.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
The IRF4/DUSP22 test detects genetic rearrangements at the 6p25.3 chromosomal region. It helps doctors classify specific types of lymphoma, particularly ALK-negative anaplastic large cell lymphoma and large B-cell lymphoma with IRF4 rearrangement, and provides prognostic information to guide treatment planning.
This test is recommended for patients whose biopsy findings suggest ALK-negative ALCL or certain large B-cell lymphomas. It is ordered in both adults and children, with IRF4-rearranged large B-cell lymphoma being more common in younger patients.
The test does not use a blood sample. It requires tumour tissue, usually obtained through a lymph node or skin biopsy performed by a clinician. The tissue is processed into an FFPE block and then submitted to the laboratory for FISH analysis.
A positive result indicates a chromosomal rearrangement in the tumour tissue. It does not independently confirm a cancer diagnosis. Your oncologist will interpret the result alongside histopathology, immunohistochemistry, and your full clinical picture before reaching a conclusion.
Some studies have found that a DUSP22 rearrangement in ALK-negative ALCL is associated with a more favourable outcome and better response to initial treatment. However, more recent research has shown variable outcomes across patient groups. Your oncologist is best placed to explain what the result means for your individual case.
At Lupin Diagnostics, the report is delivered within 8 days of sample receipt. Turnaround time may vary slightly depending on sample quality and laboratory scheduling.
No. The IRF4/DUSP22 test requires an FFPE tumour tissue block, which can only be prepared following a biopsy performed in a clinical setting. Home collection is not applicable for this test.
IRF4/DUSP22 Test: Booking, Price, and Results
